Latigo Biotherapeutics Inc. (LTGO) vs Pacira BioSciences, Inc. (PCRX)

A side-by-side comparison of Latigo Biotherapeutics Inc. and Pacira BioSciences, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

LTGO

Latigo Biotherapeutics Inc.

$1.01B

$16.74HealthcareDelayed quote: Oct 6, 2026, 12:00 PM EDT

PCRX

Pacira BioSciences, Inc.

$988M

$25.13HealthcareDelayed quote: Oct 6, 2026, 11:54 AM EDT

Total return — LTGO vs PCRX

growth of $100 · dividends reinvested · last 1y

LTGO -7.6% (-7.6%/yr)PCRX -9.3% (-9.3%/yr)LTGO compounded faster over this window

LTGO PCRX

Metrics side by side

Total return (annualized)

Metric	LTGO	PCRX
Total return (1Y)	N/A	0.84%
Total return CAGR (3Y)	N/A	-4.83%
Total return CAGR (5Y)	N/A	-12.27%
Total return CAGR (10Y)	N/A	-3.60%

LTGO is an index fund, so valuation, profitability, and per-company growth metrics don't apply — the head-to-head here is total return (price plus reinvested dividends).

Go deeper

Full LTGO analysis Full PCRX analysis Interactive comparison tool

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.